A pilot study of anafranil in the treatment of phobic states.
A pilot study of the use of Anafranil in the treatment of phobic disorders is described. Twenty-two patients were included in the investigation, 16 receiving intravenous and oral Anafranil combined and six oral Anafranil alone. After one month, four were free of phobic symptoms and 13 only mildly disabled. At six month follow-up 10 were free of symptoms and seven only mildly disabled.
D000284:Administration, Oral; D000328:Adult; D000437:Alcoholism / Q000150:complications; D001794:Blood Pressure; D002997:Clomipramine / Q000008:administration & dosage / Q000627:therapeutic use*; D003863:Depression / Q000150:complications; D003984:Dibenzazepines / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010698:Phobic Disorders / Q000150:complications / Q000188:drug therapy*; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D011674:Pulse; D013997:Time Factors
D003984:Dibenzazepines; D002997:Clomipramine